Background: Free radicals have harmful effects on cells and tissues and are thought to be responsible for the pathogenesis of many diseases including bronchial asthma. Selenium (Se), Zinc (Zn), copper (Cu), and magnesium (Mg) are trace elements required for the antioxidant enzymes and hence the optimal functions of the immune system. Changes in the levels of these elements may lead to a reduction in antioxidant activities in asthma.Objective: This study was conducted to determine serum levels of the trace elements Se, Zn, Cu, and Mg in asthmatic patients in order to evaluate the associations of these nutrients with asthma in adults Subjects and Methods: Serum Se, Zn, Cu, and Mg concentrations were measured in 100 asthmatic adult patients and 170 healthy control subjects matched for age and sex. The patients were recruited from asthma casualties, referred clinics and wards of Elshaab and Omdurman Teaching Hospital, Khartoum Sudan. Socio-demographic data and clinical history of all subjects were collected in questionnaires. Results: Serum Se and Cu levels were found to be significantly decreased in asthmatic patients compared to controls. Mean serum Se and Cu for patients were 65.8 ± 5.5Ig/l (mean ±SD) and 0.711± 0.37g/l respectively while that for controls were 78.2± 7.5 Ig/l and 0.939± 0.322g/l respectively (P value was < 0.001). On the other hand the mean serum Zn level was significantly higher in patients compared to controls (1.2 ± 0.51g/l and 0.94± 0.254g/l respectively) (P value was <0.001). No significant difference was found in the mean serum Mg level between patients and controls (16.4 ± 4.2 g/l and 16.3 ± 2.89g/l) (P value was 0.825). Conclusions:The observed changes in the levels of the trace elements which were a decrease in serum copper and selenium and an increase in zinc may affect the antioxidant enzymes' functions, and decrease the antioxidant capacity in asthma.
BACKGROUND: Hepatocellular carcinoma (HCC) is the fi fth most common malignancy in the world. In Egypt, HCC was reported to account for about 4.7% of chronic liver disease (CLD) patients. Squamous cell carcinoma antigen (SCCA) has been reported to be strongly expressed in HCC tissue hampering its extensive use in clinical practice. AIM: To evaluate the clinical usefulness of serum SCCA levels as a serological marker for early detection of HCC among high-risk patients compared to AFP. MATERIALS AND METHODS: The study comprised of three groups. Group A included 30 patients with CLD diagnosed based on clinical, laboratory, and ultrasonographical investigations; group B included 49 patients with HCC diagnostically confi rmed by spiral CT, elevated alfafetoprotein (AFP), and/or liver biopsy; and group C, the control group, included 15 healthy subjects matched for age and sex. All groups were subjected to thorough history taking, full clinical examination, and laboratory investigations including liver functions, viral markers, and AFP and SCCA estimation using ELISA technique. RESULTS: This study revealed a highly signifi cant difference between patients with HCC, CLD, and controls regarding serum SCCA levels (5.138 ± 7.689, 1.133 ± 0.516, and 0.787 ± 0.432 ng/ml, respectively). SCCA level was persistently elevated in patients with HCC with normal AFP levels representing its useful role in early detection and follow-up of patients treated for HCC. The area under the curve (AUC) of SCCA was 0.869 (95% CI 0.783-0.929), the cut-off value was established at 1.5 ng/ml with sensitivity of 77.6% and specifi city of 84.4%). The difference between AUC of SCCA and that of AFP was 0.09 which mounted statistical signifi cance. CONCLUSIONS: SCCA could represent a useful tool as a marker for detection of HCC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.